Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ACADIA Pharmaceuticals's enterprise value is MXN60,075 Mil.
ACADIA Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN1,711 Mil. Therefore, ACADIA Pharmaceuticals's EV-to-EBITDA for today is 35.10.
The historical rank and industry rank for ACADIA Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
MEX:ACAD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.07 Med: -11.42 Max: 426.76
Current: 37.23
During the past 13 years, the highest EV-to-EBITDA of ACADIA Pharmaceuticals was 426.76. The lowest was -68.07. And the median was -11.42.
MEX:ACAD's EV-to-EBITDA is ranked worse than 79.6% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs MEX:ACAD: 37.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ACADIA Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
ACADIA Pharmaceuticals's share price for today is MXN453.75.
ACADIA Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN40.072.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ACAD vs VKTX, EWTX, DNLI: EV-to-EBITDA Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's EV-to-EBITDA falls into.
ACADIA Pharmaceuticals's current Enterprise Value is MXN60,075 Mil.
ACADIA Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1,711 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (MEX:ACAD) has a EV-to-EBITDA of 35.10 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ACADIA Pharmaceuticals. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #320 out of 402 companies in the Biotechnology industry, placing it in the top 79.6%.
Is ACADIA Pharmaceuticals' EV-to-EBITDA too high?
ACADIA Pharmaceuticals' current EV-to-EBITDA is 35.10. The Biotechnology industry median EV-to-EBITDA is 12.20. ACADIA Pharmaceuticals' value of 35.10 is 187.7% above this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #320 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ACADIA Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' EV-to-EBITDA compare to VKTX and EWTX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #320 out of 402 companies for EV-to-EBITDA. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 12.20. ACADIA Pharmaceuticals' value of 35.10 is 187.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current EV-to-EBITDA of 35.10 is 187.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ACADIA Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current EV-to-EBITDA is 35.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN463.16, compared to a current price of MXN453.75 — trading 2% below its estimated fair value. The current EV-to-EBITDA is 35.10 and 187.7% above the Biotechnology industry median of 12.20. ACADIA Pharmaceuticals' overall GF Score™ is 74/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current EV-to-EBITDA is 35.10 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN453.75 is trading 2% below its estimated GF Value™ of MXN463.16.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
EV-to-EBITDA: 35.10
GF Value™: MXN463.16 vs. price of MXN453.75 (2% below fair value)
Industry Position: 187.7% above the Biotechnology median (#320 of 402)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
74GF Score
Get the complete analysis for MEX:ACAD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
